Link Pharma Chem Limited has informed the stock exchanges about receiving a GST demand order from tax authorities, disclosing significant financial implications under regulatory compliance requirements.

GST Demand Details

The Assistant Commissioner, Central GST & Central Excise, Vadodara has issued a demand order against the company for the financial year 2021-22. The order encompasses two primary components of tax demands and recoveries.

Nature of Violations

The tax authorities have identified specific contraventions in the company's GST compliance for the period 2021-22:

• Tax Declaration Mismatch: Discrepancy between tax liability declared in GSTR1 and tax paid through GSTR3B
• Excess ITC Claims: Excess Input Tax Credit availed on import of goods not reflected in GSTR-2A

Company Response and Impact

Link Pharma Chem received the demand order on January 27, 2026, and has made the disclosure in compliance with SEBI regulations. The company has assessed the financial impact as limited to the extent of the demand, penalty, and interest imposed, stating there is no material impact on its operations.

The pharmaceutical company has indicated its intention to file an appeal with the appropriate authority to contest the demand order. This legal recourse suggests the company disputes the findings of the tax authorities.

Regulatory Compliance

The disclosure was made under Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Managing Director Rishikesh Thakur signed the communication to BSE Limited, ensuring transparency with stakeholders regarding the regulatory development.

Link Pharma Chem Limited operates from its registered office in GIDC, Nandesari, Vadodara, Gujarat, and is engaged in pharmaceutical and chemical manufacturing activities.

Link Pharma Chem Ltd has filed a regulatory disclosure with BSE Limited regarding the transmission of equity shares following the demise of one of its promoters. The filing, made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, details the transfer of a significant shareholding within the promoter group.

Share Transmission Details

The disclosure pertains to the transmission of 92,808 equity shares, representing 2.09% of the company's total shareholding. The shares were transmitted following the sad demise of Mr. Shriniwas Vasantrao Thakur, who was one of the promoters of Link Pharma Chem Ltd. The transmission was made to his spouse, Mangala Shriniwas Thakur, through an off-market transfer process.

Shareholding Pattern Changes

According to the regulatory filing, the acquirer's shareholding position has changed significantly due to this transmission. Before the acquisition, Mangala Shriniwas Thakur held no shares in the company. Post-transmission, she now holds 92,808 equity shares, representing 2.09% of the total voting capital.

Company's Share Capital Structure

The filing reveals that Link Pharma Chem Ltd's total equity share capital stands at ₹44,405,680.00, divided into 4,440,568 equity shares of ₹10.00 each. This capital structure remains unchanged following the share transmission, as it represents an internal transfer within the promoter group rather than a fresh issue of shares.

Regulatory Compliance

The disclosure was filed in compliance with SEBI regulations governing substantial acquisition of shares and takeovers. Mangala Shriniwas Thakur, now classified as belonging to the promoter group, submitted the required documentation to BSE Limited's Department of Corporate Services. The filing includes all necessary details as prescribed under the regulatory framework, ensuring transparency in shareholding changes within the promoter group.